首页 > 抗体蛋白 > 抗体
Brilliant Violet 785™ anti-human CD19 Antibo
产品名称:
Brilliant Violet 785™ anti-human CD19 Antibo
产品类别:
抗体
产品编号:
302239
产品应用:
302239
[价格]
规格 价格 库存
25tests ¥ 3010 1

产品详情

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785? under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Brilliant Violet 785? excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections8 and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 302267 & 302268).

?

Clone HIB19 partially blocks anti-human CD19 clones 4G7 and SJ25C1 staining based on in-house testing

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  3. Bradbury L, et al. 1993. J. Immunol. 151:2915.
  4. Joseph A, et al. 2010. J. Virol. 84:6645. PubMed
  5. Wang X, et al. 2010. Haematologica. 95:884. (FC) PubMed
  6. Walker JD, et al. 2009. J. Immunol. 182:1548. (Block) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Hansen A, et al. 2002. Arthritis Rheum. 46:2160. (IHC)
  9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  10. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Tran TM, et al. 2020. Immunity. 51(4):750-765. PubMed
  2. Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed
  3. Arce Vargas F et al. 2018. Cancer cell. 33(4):649-663 . PubMed
  4. Ye Y, et al. 2022. Nat Commun. 13:6458. PubMed
  5. Meehan S, et al. 2019. Commun Biol. 2:229. PubMed
  6. Fajgenbaum DC, et al. 2019. J Clin Invest. 130:4451. PubMed
  7. Lindner JM, et al. 2019. Immunity. 50:668. PubMed
  8. Tauriainen J, et al. 2017. Sci Rep. 7:40354. PubMed
  9. Antonucci L, et al. 2020. Journal of Immunology Research. 3257.929861. PubMed
  10. Laing AG, et al. 2020. Nat Med. 26:1623. PubMed
  11. Lucas C, et al. 2021. Nature. Online ahead of print. PubMed
  12. Onodera T, et al. 2019. J Immunol. 203:3282. PubMed
  13. Costa A et al. 2018. Cancer cell. 33(3):463-479 . PubMed
  14. Maat H, et al. 2021. iScience. 24(5):102435. PubMed
  15. Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed
  16. Vardam-Kaur T, et al. 2021. Oncotarget. 12:2051. PubMed
  17. Vikkurthi R, et al. 2022. Nat Microbiol. 7:974. PubMed
  18. Combes AJ, et al. 2021. Nature. 591:124. PubMed
  19. Adachi Y, et al. 2019. Nat Commun. 10:3883. PubMed
  20. Ruella M, et al. 2018. Nat Med. 24:1499. PubMed
  21. Chung SH, et al. 2021. Hum Gene Ther. 32:682. PubMed
  22. Kim ST, et al. 2021. J Immunother Cancer. 9:. PubMed
  23. Garfall AL, et al. 2018. JCI Insight. 3. PubMed
  24. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  25. Friedensohn S, et al. 2018. Front Immunol. 9:1401. PubMed
  26. Kroloff M, et al. 2022. J Immunother Cancer. 10:. PubMed
RRID
AB_11218596 (BioLegend Cat. No. 302239) AB_2563442 (BioLegend Cat. No. 302240)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 95 kD
Distribution

B lineage (except plasma cells), follicular dendritic cells

Function
B cell activation and differentiation
Ligand/Receptor
Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor
Cell Type
B cells, Dendritic cells
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Tedder T, et al. 1994. Immunol. Today 15:437.
2. Bradbury L, et al. 1993. J. Immunol. 151:2915.

Gene ID
930 View all products for this Gene ID
UniProt
View information about CD19 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线